An FDA Molecular and Clinical Genetics Panel on Wednesday, Sept. 23, 2026, endorsed GRAIL Inc.’s Galleri multi-cancer blood test in a series of advisory votes, according to the Associated Press (via ABC News), NPR, CancerNetwork (opens in new tab), and Medical Daily (opens in new tab). The panel voted 10–0 that there is reasonable assurance Galleri is safe for the proposed use, 6–4 that it is effective, and 7–2 with one abstention that benefits outweigh risks. GRAIL’s own announcement gave the same tallies.

Galleri is a prescription DNA methylation blood test intended to screen adults 50 and older for signals linked to more than 50 cancer types and to predict a Cancer Signal Origin when a signal is detected. Panelists and GRAIL described it as a supplement to existing single-cancer screenings, not a standalone diagnosis, and stressed that a “no cancer signal” result does not rule out cancer, the cited outlets said.

The panel did not accept the test’s central label. AP reported that advisers balked at calling Galleri an early-detection test, saying it had not shown effectiveness for “early detection.” NPR reported that the panel recommended Galleri’s marketing tell people to keep up routine screenings and avoid describing it as an “early” detection tool. Philip Castle, director of the National Cancer Institute’s Division of Cancer Prevention, told the panel the performance data were too premature to show clinical benefit and that broad rollout “would risk harm and waste resources,” according to NPR.

AP reporting emphasized study-performance caveats FDA reviewers highlighted: in GRAIL’s primary study of about 140,000 older adults, the test detected roughly one-third of cancers diagnosed over a year, meaning it missed about two-thirds, while about two-thirds of “cancer signal detected” results were later confirmed. Advisers also flagged false alarms, weaker early-stage detection, and a lack of mortality-benefit data.

The vote came a day after The New England Journal of Medicine published the main results of NHS-Galleri, a randomized trial of more than 142,000 people in England. The trial missed its main goal: after three annual screening rounds, the group screened with Galleri did not have a significantly lower rate of stage III or IV diagnoses across 12 prespecified cancers than the control group (706 vs. 688 cases), according to CancerNetwork (opens in new tab)’s summary of the paper. The rate of stage IV diagnoses on their own was lower in the Galleri group, CancerNetwork (opens in new tab) reported. The trial was funded by GRAIL, according to the American Society of Clinical Oncology (opens in new tab).

Galleri is already sold by prescription in the U.S. AP said buyers typically pay $700 or more in cash, while NPR put the price at $949. FDA approval would likely open the door to coverage from Medicare and private insurers, AP reported, and NPR noted that Congress has approved Medicare coverage for multi-cancer tests that win FDA approval.

GRAIL welcomed the outcome. CEO Josh Ofman said in a company statement that the vote “reinforces the strength of Galleri’s clinical evidence” and that GRAIL will keep working with the FDA as it completes its review. The company has a direct financial stake in the decision: it sells the test, approval could make it eligible for insurance coverage, and it paid for the NHS-Galleri trial.

Advisory votes are non-binding. AP and GRAIL both said an FDA final decision on the premarket approval application is expected in the coming months; approval itself remains pending.